Anteris as a surgical solution will look a lot more viable to health admins when it has the backing of a multi-billion, multi-national company.
Nobody wants to sue a 300, 400, 6,7,800 $mill company, you'll only get peanuts out them.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-75
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.01 |
Change
-0.040(0.21%) |
Mkt cap ! $365.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.01 | $18.77 | $39.53K | 2.091K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.01 | 3 | 1 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |